Search

Your search keyword '"Taylor-Cousar, Jennifer L."' showing total 449 results

Search Constraints

Start Over You searched for: Author "Taylor-Cousar, Jennifer L." Remove constraint Author: "Taylor-Cousar, Jennifer L."
449 results on '"Taylor-Cousar, Jennifer L."'

Search Results

1. Cystic fibrosis

6. DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program.

7. Prioritizing sexual and reproductive health research and care for people with cystic fibrosis: A 2023 workshop report from the Cystic Fibrosis Foundation Sexual Health, Reproduction, and Gender (SHARING) Research Working Group

8. Standards for the care of people with cystic fibrosis (CF); Planning for a longer life

10. Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis

11. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective

15. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

16. Contributors

25. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

28. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis

33. Research Priorities in Pediatric Asthma Morbidity: Addressing the Impacts of Systemic Racism on Children with Asthma in the United States. An Official American Thoracic Society Workshop Report.

35. Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational study.

36. CLINICAL MANAGEMENT OF CHRONIC ORANGUTAN RESPIRATORY DISEASE SYNDROME IN THREE ADULT MALE BORNEAN ORANGUTANS (PONGO PYGMAEUS).

40. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.

42. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

49. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis and at Least OneF508delAllele: 144-Week Interim Results From a 192-Week Open-label Extension Study

Catalog

Books, media, physical & digital resources